Our biomarker-driven approach will
redefine cancer treatment.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
-
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences
-
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer
-
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma
-
Calithera Biosciences Announces 1-for-20 Reverse Stock Split
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Investors
- Clinical Trials
- Programs
- Therapeutic Areas
